cells

an Open Access Journal by MDPI

IMPACT FACTOR 6.0

Indexed in: PubMed

CITESCORE 9.0

# Nucleic Acid Therapeutics (NATs): Advances and Perspectives

Guest Editors:

**Dr. Aurélie Goyenvalle**
UVSQ, Inserm, END-ICAP, Université Paris-Saclay, Versailles, France

**Dr. Simon Guiraud**
UEVE, Inserm, Genethon, Université Paris-Saclay, Evry, France

Deadline for manuscript submissions:
**closed (20 March 2024)**

## Message from the Guest Editors

The field of nucleic acid therapeutics (NATs) has attracted a tremendous amount of interest in the past few decades. The increasing number of approved nucleic acid drugs demonstrates the potential of these therapies to treat a variety of diseases from neuromuscular disorders to cancers. Nucleic acid therapeutics act via multiple mechanisms of action, including gene silencing, activation, modulation, replacement, or editing. Continuous advances in the chemistry and design of these cutting-edge genetic drugs have led to numerous successful clinical applications, eliciting even more interest from researchers, including both academic groups and drug development companies.

The aim of this Special Issue is to cover recent advances in the field of nucleic acid therapeutics, including antisense oligonucleotides, small interfering RNA conjugates, lipid nanoparticles, and RNA and gene-editing technologies. We would like to put emphasis on their broad therapeutic potential due to the variety of mechanisms of action and the different tissues and diseases they can target. We invite contributions in the form of original research articles and reviews.

We look forward to your contributions.

*cells*

IMPACT FACTOR 6.0 | Indexed in: PubMed | CITESCORE 9.0

an Open Access Journal by MDPI

## Editors-in-Chief

**Prof. Dr. Alexander E. Kalyuzhny**
Neuroscience, UMN Twin Cities, 6-145 Jackson Hall, 321 Church St SE, Minneapolis, MN 55455, USA

**Prof. Dr. Cord Brakebusch**
Biotech Research & Innovation Centre, The University of Copenhagen, Copenhagen, Denmark

## Message from the Editorial Board

*Cells* has become a solid international scientific journal that is now indexed on SCIE and in other databases. We have successfully introduced a special issues format so that these issues serve as mini-forums in specific areas of cell science. *Cells* encourages researchers to suggest new special issues, serve as special issues editors, and volunteer to be reviewers. Our main focus will remain on cell anatomy and physiology, the structure and function of organelles, cell adhesion and motility, and the regulation of intracellular signaling, growth, differentiation, and aging. We are open to both original research papers and reviews.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.
**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, CAPlus / SciFinder, and other databases.
**Journal Rank:** JCR - Q2 (*Cell Biology*) / CiteScore - Q1 (*General Biochemistry, Genetics and Molecular Biology*)

## Contact Us

*Cells* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cells
cells@mdpi.com
𝕏@Cells_MDPI